|
WuXi PharmaTech Stage: Growth Date of Investment: 2008 Web Site : http://www.wuxiapptec.com Stock Symbol : NYSE: WX |
 |
WuXi, headquartered in Shanghai, China, is a premier contract research organization (CRO) with operations in China and the US. The Company was founded in 2000 as a provider of outsourced research chemistry lab services to the pharmaceutical industry, and has grown rapidly to become the global leader in this field. WuXi has expanded this core lab service business to include biology services, and has developed emerging capabilities in the related areas of clinical and commercial manufacturing and toxicology.
Warburg Pincus became a significant shareholder of WuXi beginning in 2008. Since Warburg Pincus’ investment, WuXi has strengthened its management team, demonstrated strong operational performance despite macro-economic headwinds, and continued to expand its product offering into higher value-added services. In April 2010, WuXi announced a $1.6 billion merger with Charles River Labs to create the first global CRO offering fully integrated early-stage drug development services to clients worldwide.
